SEC Form 4 · accession 0001179110-18-006311
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dawn Svoronos
Director
Period of report
May 3, 2018
Accepted (ET)
May 4, 2018 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 3, 2018 | A | 7,050 | $0.00 | A | 7,050 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $10.81 | May 3, 2018 | A | 42,000 | A | — | May 3, 2028 | Common Stock | 42,000 | 42,000 | D |
Explanation of responses
- F1Represents (i) 3,750 restricted stock units ("RSUs"), granted upon election to the Issuer's Board of Directors, in which 1/3 of the total RSUs will vest on the business day before each of the Issuer's three annual stockholder meetings following the date of grant and (ii) 3,300 RSUs that will vest 100% on the business day prior to the next annual stockholder meeting following the date of grant. Each RSU will be paid in the form of one share of common stock for each RSU.
- F2Represents (i) 19,500 options that will vest on the business day prior to the next annual stockholder meeting following date of grant and (ii) 22,500 options that will vest in three installments, with 1/3 vesting on the business day before each of the Issuer's three annual stockholder meetings following the date of grant.